|
Synonyms: BMS-986227 | FPA-008 | FPA008
Compound class:
Antibody
Comment: Cabiralizumab is an investigational humanized monoclonal antibody targeting the receptor tyrosine kinase, CSF1R (Fms). It is being investigated for its potential anti-cancer activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US20110274683 [1] 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Wong J, Vasquez M. (2011)
Antibodies That Bind CSF1R. Patent number: US20110274683 A1. Assignee: Five Prime Therapeutics, Inc.. Priority date: 04/05/2010. Publication date: 10/11/2011. |
